And so it begins. Cell MedX (OTCQB:CMXC) -- the company developing a bioelectric device to treat diabetes and some of its effects -- announced on Thursday morning that the first participants in a pivotal trial have been identified and approved. The testing, which should be completed within four to six months, will seek to verify that use of the company's eBalance technology lowers blood sugar for Type 1 and Type 2 diabetics. In previous observational testing, that result was seen... along with other demonstrable health benefits. The company and its shareholders are understandably excited to begin these clinical trials. The underlying science of electromedicine isn't exactly brand new, but it is understudied... especially given its potential. The premise is simple enough. That is, each cell in the human body isn't just a collection of biological structures and organic chemical reactions. By design, they also emit and respond to electrical currents. By tweaking the amount of current delivered to a damaged cell or group of cells, they can often be restored to their full functionality. Conversely, cells that are damaged beyond repair (like cancerous cells) can have their self-destruct programming bolstered by waves of electricity. Cell MedX has developed a simple but potent means to facilitate this approach to healing... a device called the eBalance. The wand, or applicator, can be applied to the body to deliver the electrical current, which isn't uncomfortable. It was put to the test in an unofficial sense last year, with the company conducting an open-ended study of its effects on everything from diabetes to pain to high blood pressure. Even with just that modest level of review Cell MedX could see its electromedicine hardware was having a positive effect for many of those participants. Based on that success, the company moved forward, announcing last week it had been granted approval by Canada's Ethics Review Board to begin an observational clinical trial in Canada; the country's top healthcare regulator, Health Canada, had already approved the trial in January. It took just a little over a week since the Ethics Review Board's green light to find the study's first approved participants. Three are confirmed as qualified participants already, and two more are already pending. All told, Cell MedX is looking for at least 30 participants, as a sample size that large will be enough to be considered statistically significant. Given the response thus far, the company shouldn't have trouble finding them. All the test subjects will receive three months of treatment with the eBalance bioelectric technology. While the primary goal is creating a reduction in glycated hemoglobin -- an indicator of blood sugar -- in the blood, the trial will also look at changes in diabetic neuropathy, kidney function, foot pain, blood pressure, and more. These are all conditions often caused or exacerbated by diabetes, but they're also conditions where cells can be restored to a healthy state by bathing them in mild electrical currents. The company has even put Parkinson's disease on its list of potential targets. In some regards it all sounds too good to be true. Insulin injections have been the only means of treating diabetes for nearly a century now, and as long as mankind has been harnessing electricity, one would think the idea would have been fully developed by now if there was something to it. This is one of those sciences, however, that has indeed been ignored for too long, only attracting fringe attention for several decades. That's changing, by the way.... one of the reasons CMXC is such an interesting prospect at this time. For example, Google and GlaxoSmithKline (GSK) recently teamed up to form a joint venture called Galvani Bioelectronics. The organization aims to create miniaturized, implantable devices to modify nerve signals that go awry with several different illnesses. The venture's chiefs believe such technologies could first address asthma, arthritis, and.... oh yeah, diabetes. In 2014, the FDA approved the Cefaly device, which treats migraines by delivering a mild electrical current from a user's forehead. Several smaller research groups are starting to work on the idea as well, though none seem as far along at Cell MedX is. In any case, we should start to hear about the trial's results sometime in the second half of this year. If the official study being performed by the Hamilton Medical Research Group (under the direction of Dr. Richard Tytus) looks anything like last year's observational reviews, there's a lot to look forward to for investors. Here's the press release. Cell MedX Corp. Announces First Subjects Screened and Qualified for the Observational Clinical Trial CARSON CITY, NV / ACCESSWIRE / March 9, 2017 / Cell MedX Corp. (CMXC), ("Cell MedX" or the "Company"), is pleased to announce that Dr. Richard Tytus, the Lead Investigator on the previously announced Observational Clinical Trial (the "Trial"), and his team at Hamilton Medical Research Group have commenced screening for qualified subjects. The group of seven potential study participants have been screened with an additional five subjects scheduled for screening. Three subjects have qualified for participation in the study and two more are pending qualification based on receipt of their bloodwork. It is expected that additional subjects will be enrolled over the next two weeks. The intent of this Observational Clinical Trial is to assess the impact of three months of eBalance therapy as an adjunct treatment, on HbA1c in Type 1 and Type 2 diabetics. The secondary endpoints of the Trial will observe changes from baseline and medical history in the following; Insulin sensitivity Diabetic neuropathy Diabetic foot pain and numbness Wound healing Blood pressure Kidney function To take into account any other changes reported by patients The Trial is being conducted over a four to six month period enrolling a minimum of 30 individuals who will receive three months of eBalance therapy. All study participants will be screened to confirm a diagnosis of either Type 1 or Type 2 diabetes. Mr. McEnulty, the Company's CEO, stated: "I am very excited to get these Observational Clinical Trials underway and am looking forward to what we at Cell MedX believe will be encouraging results." About Cell MedX Corp. Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company's newsletter, please go to www.cellmedx.com/media/newsletters/ On behalf of the Board of Directors of Cell MedX Corp. Frank McEnulty Chief Executive Officer and President. Forward Looking Statements The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports. For further information visit: www.cellmedx.com Or phone: 1-844-238-2692 SOURCE: Cell MedX Corp.